First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors (Q87255486)

From Wikidata

Jump to navigation Jump to search

scientific article published on 08 May 2015

Language	Label	Description	Also known as
English	First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors	scientific article published on 08 May 2015

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947566%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947566%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

David Geary

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947566%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Samir D Undevia

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947566%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Cinthya Coronado

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947566%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Jorge L Iglesias

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947566%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Richard L Schilsky

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947566%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Bernardo Miguel-Lillo

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947566%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

8 May 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947566%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Investigational New Drugs

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947566%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

33

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947566%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947566%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

901-910

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947566%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer treatments: can we find treasures at the bottom of the sea?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I Clinical and Pharmacokinetic Study of Kahalalide F Administered Weekly as a 1-Hour Infusion to Patients with Advanced Solid Tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kahalalide F and ES285: potent anticancer agents from marine molluscs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kahalalides: Bioactive Peptides from a Marine Mollusk Elysia rufescens and Its Algal Diet Bryopsis sp.(1)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Handling data below the limit of quantification in mixed effect models

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accelerated titration designs for phase I clinical trials in oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ways to fit a PK model with some data below the quantification limit

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25947566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-015-0247-1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947566%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25947566%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q87255486&oldid=1445578545"